BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 611
- Registration Number
- NCT00661700
BAY43-9006 Phase II Study for Renal Cell Carcinoma
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 131
- Registration Number
- NCT00661375
To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 173
- Registration Number
- NCT00661115
Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Levitra (Vardenafil, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 523
- Registration Number
- NCT00661297
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 229
- Registration Number
- NCT00657033
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)Drug: Placebo
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 541
- Registration Number
- NCT00656981
Extension Program for Bay 43-9006
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT00657254
Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia
Phase 2
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 222
- Registration Number
- NCT00657839
Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 130
- Registration Number
- NCT00657644
Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Levitra (Vardenafil, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 463
- Registration Number
- NCT00658177
© Copyright 2025. All Rights Reserved by MedPath